Ipratropium nasal
| Ipratropium nasal | |
| What is it? | Antimuscarinic |
| Mechanism of action | Antisecretory with bronchodilator properties |
| Starting dose | 41 μg (two sprays) 6–8 hourly prn |
| Time to onset of effect | 15–30 min17 |
| Formulation | Nasal spray |
| Indication | Rhinorrhoea Bronchial secretions Respiratory secretions |
| Common adverse effects | Dizziness; dry mouth; headache; urinary disorders; vision disorders; vomiting; tachycardia; GI dysmotility; oropharyngeal irritation; bronchoconstriction16 |
| Contraindications | Tachycardia >100 Cardiac conduction disorders16 |
| Caution | Narrow angle glaucoma Bladder outflow obstruction Cystic fibrosis |
| Licence | ‘off label’ use of licensed product |
| Benefits | Easy to use |
| Risks | It is unknown whether sufficient systemic absorption is achieved via the intranasal route to improve bronchial and respiratory secretions |
| Cost | £6.54 for 180×21 μg/dose nasal spray |